OACC
Oaktree Acquisition Corp. III Life Sciences
Shell Companies
Market Cap$261M
5Y Perf.+6.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OACC vs BCTX
Revenue, margins, valuation, and 5-year total return — side by side.
BCTX
BriaCell Therapeutics Corp.
Biotechnology
Market Cap$5M
5Y Perf.-95.2%
OACC vs BCTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OACC | BCTX |
|---|---|---|
| Industry | Shell Companies | Biotechnology |
| Market Cap | $261M | $5M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $5M | $-38M |
| Forward P/E | 195.8x | — |
| Total Debt | $12K | $0.00 |
| Cash & Equiv. | $1M | $14M |
OACC vs BCTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OACC
BCTX
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Oaktree Acquisition… (OACC) | 100 | 106.5 | +6.5% |
| BriaCell Therapeuti… (BCTX) | 100 | 4.8 | -95.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OACC vs BCTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: OACC leads in 4 of 5 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
OACC
Oaktree Acquisition Corp. III Life Sciences
The Banking Pick
OACC carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.08
- 6.1% 10Y total return vs BCTX's -99.2%
- Lower volatility, beta 0.08, Low D/E 0.0%, current ratio 2.14x
Best for: income & stability and long-term compounding
BCTX
BriaCell Therapeutics Corp.
The Specific-Use Pick
In this particular matchup, BCTX is outpaced on most metrics by others in the set.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | OACC | 0.8% margin vs BCTX's 0.4% |
| Stability / Safety | OACC | Beta 0.08 vs BCTX's 1.56 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | OACC | +1.4% vs BCTX's -87.5% |
| Efficiency (ROA) | OACC | 2.6% ROA vs BCTX's -153.6% |
OACC vs BCTX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOACCLAGGINGBCTX
BCTXBriaCell Therapeutics…
1leads
OACCOaktree Acquisition C…
3leads
6 Total Categories
CATEGORYLEADERvs BCTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
BCTX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OACC4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
OACC5/5
Risk & VolatilityBeta, volatility, and downside exposure
OACC2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
OACC and BCTX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | OACCOaktree Acquisiti… | BCTXBriaCell Therapeu… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$847,195 | -$43M |
| Net IncomeAfter-tax profit | $5M | -$38M |
| Free Cash FlowCash after capex | -$278,200 | -$37M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +92.3% |
Insufficient data to determine a leader in this category.
Valuation Metrics
BCTX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | OACCOaktree Acquisiti… | BCTXBriaCell Therapeu… |
|---|---|---|
| Market CapShares × price | $261M | $5M |
| Enterprise ValueMkt cap + debt − cash | $259M | -$9M |
| Trailing P/EPrice ÷ TTM EPS | 195.76x | -0.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 9999.00x | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.39x | 0.32x |
| Price / FCFMarket cap ÷ FCF | — | — |
BCTX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
OACC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
OACC delivers a 0.0% return on equity — every $100 of shareholder capital generates $0 in annual profit, vs $-194 for BCTX. On the Piotroski fundamental quality scale (0–9), OACC scores 4/9 vs BCTX's 1/9, reflecting mixed financial health.
| Metric | OACCOaktree Acquisiti… | BCTXBriaCell Therapeu… |
|---|---|---|
| ROE (TTM)Return on equity | +0.0% | -193.8% |
| ROA (TTM)Return on assets | +2.6% | -153.6% |
| ROICReturn on invested capital | — | -12.6% |
| ROCEReturn on capital employed | -0.0% | -3.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$1M | -$14M |
| Cash & Equiv.Liquid assets | $1M | $14M |
| Total DebtShort + long-term debt | $11,824 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -796.67x |
OACC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
OACC leads this category, winning 5 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OACC five years ago would be worth $10,610 today (with dividends reinvested), compared to $83 for BCTX. Over the past 12 months, OACC leads with a +1.4% total return vs BCTX's -87.5%. The 3-year compound annual growth rate (CAGR) favors OACC at 2.0% vs BCTX's -84.4% — a key indicator of consistent wealth creation.
| Metric | OACCOaktree Acquisiti… | BCTXBriaCell Therapeu… |
|---|---|---|
| YTD ReturnYear-to-date | -0.0% | -42.8% |
| 1-Year ReturnPast 12 months | +1.4% | -87.5% |
| 3-Year ReturnCumulative with dividends | +6.1% | -99.6% |
| 5-Year ReturnCumulative with dividends | +6.1% | -99.2% |
| 10-Year ReturnCumulative with dividends | +6.1% | — |
| CAGR (3Y)Annualised 3-year return | +2.0% | -84.4% |
OACC leads this category, winning 5 of 5 comparable metrics.
Risk & Volatility
OACC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
OACC is the less volatile stock with a 0.08 beta — it tends to amplify market swings less than BCTX's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OACC currently trades 98.8% from its 52-week high vs BCTX's 11.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OACCOaktree Acquisiti… | BCTXBriaCell Therapeu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.08x | 1.56x |
| 52-Week HighHighest price in past year | $10.74 | $37.20 |
| 52-Week LowLowest price in past year | $10.30 | $3.60 |
| % of 52W HighCurrent price vs 52-week peak | +98.8% | +11.0% |
| RSI (14)Momentum oscillator 0–100 | 47.6 | 50.0 |
| Avg Volume (50D)Average daily shares traded | 38K | 185K |
OACC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | OACCOaktree Acquisiti… | BCTXBriaCell Therapeu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
OACC leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). BCTX leads in 1 (Valuation Metrics).
Best OverallOaktree Acquisition Corp. I… (OACC)Leads 3 of 6 categories
Loading custom metrics...
OACC vs BCTX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is OACC or BCTX a better buy right now?
Oaktree Acquisition Corp.
III Life Sciences (OACC) offers the better valuation at 195. 8x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OACC or BCTX?
Over the past 5 years, Oaktree Acquisition Corp.
III Life Sciences (OACC) delivered a total return of +6. 1%, compared to -99. 2% for BriaCell Therapeutics Corp. (BCTX). Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OACC or BCTX?
By beta (market sensitivity over 5 years), Oaktree Acquisition Corp.
III Life Sciences (OACC) is the lower-risk stock at 0. 08β versus BriaCell Therapeutics Corp. 's 1. 56β — meaning BCTX is approximately 1829% more volatile than OACC relative to the S&P 500.
04Which has better profit margins — OACC or BCTX?
Oaktree Acquisition Corp.
III Life Sciences (OACC) is the more profitable company, earning 0. 0% net margin versus 0. 0% for BriaCell Therapeutics Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OACC leads at 0. 0% versus 0. 0% for BCTX. At the gross margin level — before operating expenses — OACC leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — OACC or BCTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is OACC or BCTX better for a retirement portfolio?
For long-horizon retirement investors, Oaktree Acquisition Corp.
III Life Sciences (OACC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 08)). BriaCell Therapeutics Corp. (BCTX) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between OACC and BCTX?
These companies operate in different sectors (OACC (Financial Services) and BCTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.